Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...
Potential approvals of new medicines expected soon could push these stocks through the roof.
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
The biotech company saw strong results in a phase 3 trial.
Monday was a good day for biotechs fighting the good fight against a common degenerative brain disorder.